Clinical referenceGuideUpdated 10 November 2026

The best OpenEvidence alternative in Australia (2026)

In this guide, EvidenceMD ranks first for Australian clinicians looking for an OpenEvidence alternative in 2026. It is a clinical reasoning platform: it answers clinical questions from 40 million+ peer-reviewed papers and clinical guidelines and shows its full chain-of-thought reasoning, with a citation behind every claim, so you can check each step before you act [1]. It frames the Australian parts of an answer to Australian guidance and answers in 30 languages [1]. Any Ahpra-registered doctor, nurse practitioner or pharmacist can start without a US NPI or a licence check [2].

OpenEvidence becomes unavailable across the EU and the UK
27 Apr 2026OpenEvidence becomes unavailable across the EU and the UK
OpenEvidence registration asks for a US NPI or, as applicable, another licensing number
NPIOpenEvidence registration asks for a US NPI or, as applicable, another licensing number
Reasonable steps before personal information goes to an overseas recipient
APP 8Reasonable steps before personal information goes to an overseas recipient
The TGA's amended clinical decision support exemption takes effect
1 Nov 2026The TGA's amended clinical decision support exemption takes effect
By the EvidenceMD Editorial TeamGuidePublished 10 November 202612 min read

Medically reviewed by Dr. Abishek Shahi, Harvard-trained Physician · Last reviewed 10 November 2026

What is the best OpenEvidence alternative in Australia in 2026?

QUICK ANSWER

EvidenceMD is the best OpenEvidence alternative in Australia in 2026: it shows its full chain-of-thought clinical reasoning with a citation for every claim, and any Ahpra-registered clinician can start without an NPI. It searches 40 million+ peer-reviewed papers and clinical guidelines, frames the Australian parts of an answer to Australian guidance, and is free to start [1][2]. Heidi Evidence is a strong second: free for individual clinicians, and hosted in Australia by Heidi's account [11][14]. ClinicalKey AI sells individual plans in Australia, AMBOSS includes AI Mode in its subscriptions, and UpToDate Expert AI reaches Australians through hospital licences [15][16][17][18]. OpenEvidence's own route here is narrow: a separate subscription product, no Australian price on its public pages, and a sign-up built around the US NPI [6][7][8]. EvidenceMD is hosted in the United States, so describe cases without identifiers [3].

OpenEvidence alternatives in Australia: EvidenceMD and the rest. EvidenceMD versus Heidi Evidence, ClinicalKey AI, AMBOSS, UpToDate Expert AI on Reasoning shown, Evidence base, Sign-up in Australia, Australian prescribing, Data location.
EvidenceMD compared with Heidi Evidence, ClinicalKey AI, AMBOSS and UpToDate Expert AI for Australian clinicians: EvidenceMD shows its reasoning step by step with a citation for every claim and needs no NPI; the others give cited answers from curated or vendor content, through free plans, subscriptions or hospital licences.

Key takeaways

  • EvidenceMD ranks first because it shows how it reached an answer, cites the source behind each claim, and opens to any Australian clinician without an NPI, which makes Ahpra's expectation that you apply human judgement to AI output practical [1][19].
  • OpenEvidence's Australian route is narrow. Its terms ask for an NPI or, as applicable, another professional licensing number and let it refuse an account; a NSW Health library describes OpenEvidence Australia as a subscription with two free searches a week; and on 10 November 2026 its iOS app was not listed in the Australian App Store [6][8][9].
  • Heidi Evidence is free for individual clinicians, answers with citations and verbatim excerpts, prioritises sources aligned to your region, and Heidi says it hosts its data in Australia [11][12][14].
  • ClinicalKey AI sells individual subscriptions in Australia with a 90-day free trial, AMBOSS includes AI Mode in its subscriptions, and UpToDate Expert AI is sold to individuals only in the US and Canada, so Australians reach it through an enterprise licence [15][16][17][18].
  • eTG complete and AMH are not AI answer engines. They are the independent Australian references for treatment and medicines, and they stay where you confirm a drug, a dose or a local recommendation [20][21].
  • The rules do not change with the tool. Ahpra keeps you responsible for any AI output, APP 8 applies when personal information goes offshore, and the TGA's clinical decision support exemption expects software to show the logic behind a recommendation [19][22][24].

Why are Australian clinicians looking for an OpenEvidence alternative?

OpenEvidence has not left Australia, but it was built for US clinicians, and its own documents show it.

OpenEvidence's Terms of Use, last updated 17 September 2026, say that registration requires a National Provider Identifier or, as applicable, another professional licensing number, that OpenEvidence may try to verify it, and that it may refuse to issue an account at its discretion [6]. The same terms say the service is not available in the European Union, the United Kingdom or the European Economic Area; it went dark there on 27 April 2026 [6][10]. Australia is not on that list.

What Australia gets instead is a separate product. OpenEvidence's website carries the notice "OpenEvidence Australia is now available" [7], and the Northern Sydney Local Health District library guide, updated on 10 November 2026, describes OpenEvidence Australia as a subscription-based tool whose free account gives two searches a week [8]. We found no Australian price on OpenEvidence's public pages, and when we checked on 10 November 2026 its iOS app, which is listed in the US, Canadian and New Zealand App Stores, had no listing in the Australian App Store [9].

So the question for an Australian clinician is not whether OpenEvidence answers well; its answers are fast and cited. It is whether you can count on getting it, at a known price, through a licence check that recognises Ahpra registration. If you cannot, you need a tool that does the same job: answer a clinical question with citations you can open, on a sign-up that works in Australia.

In short

OpenEvidence is still reachable from Australia, but as a subscription product with a two-search weekly free tier, no published Australian price and a sign-up built around the US NPI [6][8]. EvidenceMD answers the same kind of question with a citation for every claim, and an Ahpra-registered clinician can start without an NPI [1][2].

What should an OpenEvidence alternative do for an Australian clinician?

Five things, most of them set by Australian rules rather than by taste.

Citations you can open

Every claim linked to a source you can read, because Ahpra expects you to apply human judgement to any AI output before you act on it [19].

Reasoning, not only a summary

Multimorbidity, renal dosing and atypical presentations need the steps that led to an answer, not only the conclusion, so you can find the step that does not fit your patient.

A sign-up that works here

No US NPI, no US-only plan and no verification step that may not recognise Ahpra registration [6][18].

Data handling you can explain

Where the vendor stores data and whether it trains on it, so you can take the reasonable steps APP 8 asks for before personal information leaves Australia [19][22].

Room for Australian prescribing

Answers that send you to Australian sources for drug choice and dose, with eTG complete and AMH still the place to confirm them [20][21].

What an OpenEvidence alternative must do in Australia: Citations, Reasoning, Sign-up, Data, Prescribing.
Five things an OpenEvidence alternative must do for an Australian clinician: citations you can open, reasoning you can follow, a sign-up that works without a US NPI, data handling you can explain under APP 8, and room for Australian prescribing in eTG and AMH.

Which OpenEvidence alternatives can Australian clinicians actually sign up for in 2026?

Ranked on four things: citations you can check, reasoning you can follow, whether an Australian clinician can get the AI, and how its data is handled.

  1. EvidenceMD: best overall OpenEvidence alternative in Australia

    EvidenceMD searches 40 million+ peer-reviewed papers and clinical guidelines before it answers, then streams its chain-of-thought clinical reasoning with an inline citation for every claim, so you can follow each step and open each source [1]. It frames the Australian parts of an answer to Australian guidance, answers in 30 languages, needs no NPI or licence check, and is free to start, with paid individual plans from US$50 a month [1][2]. For longer questions it writes cited DeepSearch reports, and it reports 54.6% on HealthBench Hard, a self-reported figure [4][5]. Limit: application data is stored on Microsoft Azure in East US 2 (Virginia, United States), so APP 8 applies to anything identifiable; it is not included in the ARTG; and SOC 2 Type II is in progress, not complete [3][22].

  2. Heidi Evidence: best free option inside a scribe platform

    Heidi Evidence, from the Melbourne company behind the Heidi scribe, answers clinical questions with inline citations and verbatim excerpts from curated sources, and its named partners include HealthPathways, MIMS, NICE and BMJ Group [11][12]. Heidi says it is free for individual clinicians, with unlimited use outside consultations on every plan, and that it hosts its data in Australia [11][13][14]. Limit: it gives cited answers rather than step-by-step reasoning, partner sources such as HealthPathways and BMJ Best Practice sit on paid plans, and the free plan caps in-consultation use at 10 a month [12][13].

  3. ClinicalKey AI: Elsevier full text, sold to individuals in Australia

    ClinicalKey AI answers from Elsevier's journals and reference books, plus sources such as the New England Journal of Medicine and society guidelines, with citations that trace back to the paragraph [15]. Elsevier lists Australia among the countries where individual subscriptions are sold, with a 90-day free trial [15]. Limit: it is paid after the trial, its guideline additions are led by US societies such as ACC, CHEST and ACEP, and it summarises rather than showing its reasoning step by step [15].

  4. AMBOSS: AI Mode inside an AMBOSS subscription

    AMBOSS AI Mode answers from AMBOSS's own library, AMBOSS Drugs and selected external sources, including US clinical guidelines and a drug database, and it is currently included in all AMBOSS subscriptions [16]. Limit: AMBOSS says AI Mode is intended for medical research and not for diagnostic or therapeutic use, that functions may differ by country to meet local regulations, and that new users may wait several weeks for access [16].

  5. UpToDate Expert AI: for clinicians whose hospital licenses it

    Expert AI answers only from UpToDate's expert-written content, and Wolters Kluwer says it explains its reasoning and highlights its assumptions [17]. In Australia it reaches clinicians through an enterprise-wide UpToDate subscription; the Pro Plus package that adds Expert AI for individual subscribers is offered in the United States and Canada [17][18]. Limit: there is no personal route to Expert AI in Australia as of November 2026, and Wolters Kluwer says it is treated as clinical decision support in some jurisdictions and as a reference-only tool in others [17].

OpenEvidence alternatives for Australian clinicians compared, from each vendor's own pages (November 2026)
ToolAnswers fromShows its reasoningHow an Australian clinician gets the AIWhere data is hosted
EvidenceMD40M+ peer-reviewed papers and clinical guidelinesYes, full chain-of-thought clinical reasoning with a citation for every claimFree to start, no NPI or licence check [2]United States (Azure East US 2) [3]
Heidi EvidenceCurated guidelines, medicines references and researchCited answers with verbatim excerptsFree for individual clinicians; partner sources on paid plans [11][12]Australia, according to Heidi [14]
ClinicalKey AIElsevier full text, NEJM and society guidelinesCited summaries traced to the paragraphIndividual subscription sold in Australia, 90-day trial [15]Not stated for Australia
AMBOSSAMBOSS library, US guidelines, drug databaseSummaries linked to sourcesIncluded in AMBOSS subscriptions; functions may differ by country [16]Not stated for Australia
UpToDate Expert AIUpToDate's expert-written topics onlyExplains reasoning and assumptionsThrough an enterprise licence; personal plans in the US and Canada only [17][18]Not stated for Australia

→ Scroll the table sideways to see the remaining columns

What about DynaMed?

DynaMed is a strong reference, and many Australians reach it through a college or health service, but EBSCO says DynaMed with Dyna AI for individual subscribers is currently available only in the USA, so it is not ranked here as an AI answer engine [25].

How does EvidenceMD answer a question an Australian GP might ask?

A de-identified case, the evidence behind each step, and a next step framed to Australian practice.

Take a question a GP in regional Victoria might ask between patients: a man in his early sixties with type 2 diabetes, an eGFR of 48 mL/min/1.73 m² and a urine albumin-to-creatinine ratio of 35 mg/mmol, already on metformin and perindopril. Should an SGLT2 inhibitor be added for his kidneys, and how strong is the evidence?

EvidenceMD starts with an assessment: chronic kidney disease with an eGFR in the 45 to 59 range and severely increased albuminuria, a combination with a high risk of progression. It then sets out the evidence and cites it at the sentence. In DAPA-CKD, 4,304 people with an eGFR of 25 to 75 and albuminuria were randomised to dapagliflozin or placebo; the primary kidney and cardiovascular outcome fell (hazard ratio 0.61), with similar effects with and without type 2 diabetes [26]. In EMPA-KIDNEY, 6,609 people were randomised to empagliflozin or placebo, and progression of kidney disease or cardiovascular death fell (hazard ratio 0.72) [27].

The recommendation follows from that evidence: add an SGLT2 inhibitor alongside the ACE inhibitor unless there is a contraindication, with sick-day advice to pause it during acute illness, and a plan to recheck kidney function after starting. The next step is framed to Australian practice: confirm the PBS listing and the dose in AMH or Therapeutic Guidelines before you prescribe, and check your local HealthPathways for referral thresholds [1][20][21]. You see every step and every source, so you can change the plan where this patient differs from the trial populations.

Ask EvidenceMD the same question

Describe a case without identifiers and read the reasoning and the sources behind the answer.

Try EvidenceMD

Where do eTG complete and AMH fit next to an AI answer engine?

They are Australian references, not AI answer engines, and they do a different job.

Therapeutic Guidelines, the product many clinicians still call eTG complete, is published by an independent not-for-profit organisation and gives treatment advice for about 2,500 conditions across 22 guidelines [20]. The Australian Medicines Handbook is independent, peer-reviewed medicines information written for Australian health professionals [21]. Both are edited references you look things up in; neither answers a free-text clinical question the way OpenEvidence or EvidenceMD does.

That makes them partners to an AI answer engine rather than rivals. Use an engine such as EvidenceMD to work through the question, weigh the trials and see what the international evidence says, then confirm the Australian specifics, such as the first-line agent, the dose, the PBS restriction and the duration, in Therapeutic Guidelines or AMH before you prescribe [1][20][21].

A simple division of labour

AI answer engine for the question and the evidence; Therapeutic Guidelines and AMH for Australian drug choice and dose; your local HealthPathways for referral. EvidenceMD points you to the Australian check rather than replacing it.

What do Ahpra, the Privacy Act and the TGA expect when you put clinical questions to AI?

Three rules matter most for an answer engine. This is not legal advice; our Australian guides cover each in depth [28][29].

Ahpra. Its guidance on meeting your professional obligations when using AI says you remain responsible for safe and quality care, must apply human judgement to any AI output, and that TGA approval of a tool does not change that duty; it also asks you to understand where a tool stores data and whether it uses it to retrain the model [19].

Privacy Act and APP 8. Health information is sensitive information. APP 8.1 does not ban disclosure to an overseas recipient, but it requires reasonable steps first, and section 16C can make you accountable for what that recipient does [22]. The simplest step with any overseas tool, EvidenceMD included, is not to disclose personal information at all: describe the case, not the patient.

TGA. Software that meets the definition of a medical device must generally be in the ARTG unless it is exempt [23]. From 1 November 2026 the clinical decision support exemption applies only to software that is not intended to make a diagnosis or treatment decision and that displays the guidelines, calculations or logic behind each recommendation so a health professional can verify it [24]. Ask any vendor how its product is classified; EvidenceMD is not included in the ARTG.

EvidenceMD and Australian patient data

EvidenceMD stores application data on Microsoft Azure in East US 2 (Virginia, United States) and does not train on your conversations [3]. Leave out names, Medicare numbers, addresses, exact dates and rare details: "man, early sixties, T2DM, eGFR 48, ACR 35" is enough for a clinical question.

When is EvidenceMD not the right OpenEvidence alternative?

Three situations where another tool on this page is the better fit.

Your service requires onshore data

If your health service or practice policy requires data to stay in Australia, EvidenceMD's US hosting rules it out for anything identifiable. Heidi says it hosts its data in Australia [3][14].

You already document in Heidi

If your practice runs the Heidi scribe, Heidi Evidence sits inside the same workspace, which may matter more than reasoning depth [11][12].

Your hospital licenses UpToDate Expert AI

If your health service already provides Expert AI, use it for questions UpToDate's topics cover well, and keep EvidenceMD for questions those topics do not reach [17].

How do you switch from OpenEvidence safely in Australian practice?

Five steps, from a de-identified question to your own decision.

  1. Check what your employer allows

    Public health services and practices may have an approved-tools list or an AI policy. Use that first for anything involving patient records [19].

  2. Describe the case, not the patient

    Age range, key findings, medicines and the decision you face, with no name, Medicare number or address, so nothing identifiable goes offshore [22].

  3. Open the sources behind the steps that matter

    Read the citations behind any step that changes your plan, and check they say what the answer claims.

  4. Confirm the Australian specifics

    Check drug choice, dose and PBS restriction in Therapeutic Guidelines or AMH, and referral in your local HealthPathways [20][21].

  5. Decide and document

    The decision is yours, and Ahpra holds you responsible for it. Record your reasoning in your own clinical system [19].

Switching from OpenEvidence safely in Australia: 1 Check, 2 De-identify, 3 Verify, 4 Localise, 5 Decide.
Five steps for switching from OpenEvidence safely in Australian practice: check what your employer allows, describe the case not the patient, open the sources behind the key steps, confirm Australian specifics in eTG or AMH, then decide and document.

Frequently asked questions

What is the best OpenEvidence alternative in Australia?

EvidenceMD is the best OpenEvidence alternative in Australia in 2026. It answers clinical questions from 40 million+ peer-reviewed papers and clinical guidelines, shows its chain-of-thought clinical reasoning with a citation for every claim, and any Ahpra-registered clinician can start without an NPI. Heidi Evidence, ClinicalKey AI, AMBOSS and UpToDate Expert AI follow.

Which clinical AI can an Ahpra-registered clinician sign up for without a US NPI?

EvidenceMD needs no NPI or licence check. Heidi Evidence is free for individual clinicians, ClinicalKey AI sells individual subscriptions in Australia, and AMBOSS includes AI Mode in its subscriptions. OpenEvidence's registration asks for an NPI or, as applicable, another licensing number and may refuse an account.

Is Heidi Evidence a good OpenEvidence alternative for Australian clinicians?

Yes, it is a strong second choice. Heidi says Evidence is free for individual clinicians, answers with citations and verbatim excerpts, prioritises sources aligned to your region and hosts its data in Australia. It does not show step-by-step reasoning; EvidenceMD ranks first because it does.

Can individual clinicians in Australia subscribe to ClinicalKey AI?

Yes. Elsevier lists Australia among the countries where ClinicalKey AI individual subscriptions are sold, with a 90-day free trial, and it answers from Elsevier full text and society guidelines. EvidenceMD differs by showing its reasoning step by step and by searching the wider peer-reviewed literature.

Is AMBOSS AI Mode suitable for practising clinicians in Australia?

It is useful for fast lookups in AMBOSS content, and it is included in AMBOSS subscriptions. AMBOSS says AI Mode is intended for medical research, not diagnostic or therapeutic use, that it draws on US guidelines and that functions may differ by country. EvidenceMD frames Australian parts of an answer to Australian guidance.

Does OpenEvidence leaving the EU and UK in 2026 affect clinicians in Australia?

Not directly: OpenEvidence's terms exclude the EU, the UK and the EEA, and Australia is not on that list. It does show how quickly access can change for clinicians outside the US. EvidenceMD is available in Australia with no NPI, and a second tool such as Heidi Evidence is a sensible backup.

Do eTG complete and AMH have AI answers like OpenEvidence?

No. Therapeutic Guidelines (formerly eTG complete) and the Australian Medicines Handbook are independent Australian references you look up, not AI answer engines. Use an engine such as EvidenceMD for the clinical question and the evidence, then confirm drug choice and dose in Therapeutic Guidelines or AMH.

Which OpenEvidence alternative keeps Australian data in Australia?

Heidi says it hosts its data in Australia. EvidenceMD stores application data in the United States (Microsoft Azure East US 2), so use EvidenceMD with de-identified questions only, and choose an onshore tool if your health service requires data to stay in Australia.

Does APP 8 stop Australian clinicians using an overseas AI tool?

No, but it requires reasonable steps before personal information goes to an overseas recipient, and section 16C can make you accountable for that recipient. With EvidenceMD, which is hosted in the United States, the simplest approach is to disclose nothing personal: describe the case, not the patient.

How does the TGA's November 2026 change affect AI clinical answer tools?

From 1 November 2026 the clinical decision support exemption covers only software that is not meant to make a diagnosis or treatment decision and that displays the guidelines, calculations or logic behind each recommendation. Ask every vendor how its product is classified. EvidenceMD is not included in the ARTG, and its answers are for clinicians to check, with the decision left to you.

What does an OpenEvidence alternative cost an Australian clinician?

EvidenceMD is free to start, with paid individual plans from US$50 a month or US$450 a year. Heidi Evidence is free for individual clinicians, ClinicalKey AI is paid after a 90-day trial, AMBOSS is a paid subscription, and UpToDate Expert AI comes through a hospital licence in Australia.

The bottom line

For Australian clinicians replacing OpenEvidence in 2026, EvidenceMD is the best overall choice: it shows its chain-of-thought clinical reasoning with a citation for every claim, frames the Australian parts to Australian guidance, and opens to any Ahpra-registered clinician without an NPI [1][2]. Heidi Evidence is the strongest free second tool and keeps its data in Australia by Heidi's account, ClinicalKey AI is a sound paid option, AMBOSS suits AMBOSS subscribers, and UpToDate Expert AI is worth using where your hospital licenses it [11][14][15][16][17]. Whatever you use, confirm Australian prescribing in Therapeutic Guidelines or AMH, keep identifiable data out of tools hosted overseas, EvidenceMD included, and keep the decision with you [3][19][20][21][22].

Sources & related evidence

EvidenceMD's own pages (company claims), OpenEvidence's terms, website and app listing, a NSW Health library guide, the other vendors' own pages, Ahpra, the OAIC, the TGA and federal legislation, two trials for the worked example, and our two Australian guides. Checked on 10 November 2026.

  1. Source 1. EvidenceMD clinical reasoningEvidenceMD. Answers from 40 million+ peer-reviewed papers and clinical guidelines with a visible chain of reasoning and a citation for every claim; country-specific parts of an answer framed to the user's country guidelines; 30 languages; no NPI or licence check.
  2. Source 2. EvidenceMD pricingEvidenceMD. Free to start; paid individual plans from US$50 a month or US$450 a year.
  3. Source 3. EvidenceMD Trust CenterEvidenceMD. Application data is stored on Microsoft Azure in East US 2 (Virginia, United States); conversations are not used to train or fine-tune models; data is encrypted at rest and in transit; SOC 2 Type II is in progress, not complete.
  4. Source 4. EvidenceMD DeepSearchA cited report of typically 20–25 pages from one clinical or biomedical question, usually in one to three minutes.
  5. Source 5. EvidenceMD benchmark results and methodology54.6% on HealthBench Hard, with the method used. Self-reported by the company.
  6. Source 6. OpenEvidence — Terms of Use (last updated 17 September 2026)Registration requires a National Provider Identifier (or, as applicable, another professional licensing number), which OpenEvidence may attempt to verify, and OpenEvidence may refuse to issue an account in its discretion. The services are not available in the EU, the UK, the EEA or any country subject to a US trade embargo. Read from the Internet Archive capture of 9 October 2026, because the live page did not load from our location.
  7. Source 7. OpenEvidence — website notice: "OpenEvidence Australia is now available"OpenEvidence's homepage, in the Internet Archive capture of 10 November 2026, carries the notice "OpenEvidence Australia is now available!" with a "Learn more" link and describes the product as free for verified US clinicians. No Australian price was found on its public pages.
  8. Source 8. Northern Sydney Local Health District Libraries — AI literature search and mapping toolsA NSW Health library guide, last updated 10 November 2026, describing OpenEvidence Australia as a subscription-based tool with a free account giving two free searches a week.
  9. Source 9. Apple App Store (Australia) — OpenEvidenceOn 10 November 2026 Apple's Australian App Store returned no listing for OpenEvidence's iOS app (id 6612007783), which is listed in the US, Canadian and New Zealand stores as "NPI Required" and free for verified US clinicians.
  10. Source 10. The Lancet Regional Health – Europe — The need for regulatory certainty on medical AI (2026)Letter: on 27 April 2026 OpenEvidence became unavailable across the European Union and the United Kingdom, citing regulatory uncertainty related to the EU AI Act.
  11. Source 11. Heidi — Heidi Evidence launches (Heidi Health, Australian site)Heidi Evidence, a clinical research tool inside the Heidi platform, announced on 24 February 2026 with partners including HealthPathways, EMGuidance, MIMS, Vidal, NICE and BMJ Group; Heidi says it is free for individual clinicians and gives transparent citations and verbatim excerpts.
  12. Source 12. Heidi Help Center — Get started with Heidi EvidenceEvidence searches curated clinical sources such as guidelines, medicine references and published research, aims to prioritise sources aligned to your region, and makes every answer checkable with citations and source excerpts; partner sources such as HealthPathways, BMJ Best Practice and Vidal are available on paid plans.
  13. Source 13. Heidi Help Center — Heidi's pricing plans: cost and featuresEvidence outside consultations is unlimited on all plans, including Free; inside consultations it is limited to 10 uses a month on Free and unlimited on paid Evidence plans.
  14. Source 14. Heidi — APP complianceHeidi states that it prioritises data sovereignty by ensuring all its data is locally hosted within Australia. Vendor statement.
  15. Source 15. Elsevier — ClinicalKey AI for individual cliniciansIndividual subscriptions are available in countries including the US, Canada, the UK, Australia and New Zealand, with a 90-day free trial. Answers are backed by citations traceable to the exact paragraph, drawing on Elsevier full text, NEJM, abstracts from 1,100+ journals and clinical practice guidelines from societies including ACC, AACE, CHEST, ACEP and AGA.
  16. Source 16. AMBOSS — Clinical AI ModeAI Mode draws on the AMBOSS knowledge base, AMBOSS Drugs and selected external sources including US clinical guidelines and a drug database; it is currently included in all AMBOSS subscriptions, is intended for medical research and not for diagnostic or therapeutic use, may differ by region to conform to local regulations, and may have a waiting period of several weeks.
  17. Source 17. Wolters Kluwer — UpToDate Expert AI (Australian site)Expert AI draws only on UpToDate content, explains its reasoning and highlights assumptions; it is available to clinicians in health systems with an enterprise-wide UpToDate subscription; availability and features vary by region; it is considered a clinical decision support tool in some jurisdictions and a reference-only tool in others.
  18. Source 18. Wolters Kluwer — UpToDate Pro PlusThe UpToDate Pro Plus package, which features Expert AI, is available as a package option for professional subscribers in the United States and Canada.
  19. Source 19. Ahpra — Meeting your professional obligations when using AI in healthcareThe practitioner remains responsible for delivering safe and quality care, must apply human judgement to any output of AI, and TGA approval of a tool does not change that responsibility; practitioners should understand how data is used to retrain the AI, where it is located and how it is stored, and obtain informed consent. Page reviewed 22 August 2024.
  20. Source 20. Therapeutic GuidelinesAn independent not-for-profit organisation; 22 comprehensive guidelines with treatment advice for 2,500 conditions. The product was formerly called eTG complete.
  21. Source 21. Australian Medicines HandbookIndependent, peer-reviewed medicines information for Australian health professionals.
  22. Source 22. OAIC — APP guidelines, Chapter 8: cross-border disclosure of personal informationAPP 8.1 requires reasonable steps before disclosing personal information to an overseas recipient; section 16C makes the disclosing entity accountable for an overseas recipient's act or practice that would breach the APPs.
  23. Source 23. TGA — Clinical decision support system exemption amendments (8 September 2026)CDSS that meets the definition of a medical device must generally be included in the ARTG unless exempt or excluded; the amendments take effect from 1 November 2026 and, the TGA says, do not change the exemption's scope or introduce new requirements.
  24. Source 24. Federal Register of Legislation — Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026 (F2026L01167)From 1 November 2026, item 2.15 of Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002 covers clinical decision support software only if, among other limbs, it is not intended to make a clinical diagnosis or treatment decision and displays the guidelines, calculations or logic it uses so a health professional can readily interpret and verify its recommendations.
  25. Source 25. EBSCO — DynaMed storeDynaMed at US$399 a year with a 14-day free trial; DynaMed with Dyna AI for individual subscribers is currently only available in the USA.
  26. Source 26. Heerspink HJL et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med 2020;383:1436–464,304 participants with an eGFR of 25 to 75 and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g; primary composite outcome hazard ratio 0.61 (95% CI 0.51 to 0.72); effects similar with and without type 2 diabetes.
  27. Source 27. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–276,609 patients; progression of kidney disease or death from cardiovascular causes hazard ratio 0.72 (95% CI 0.64 to 0.82); results consistent with or without diabetes.
  28. Source 28. Best medical AI for doctors in Australia (EvidenceMD)The Australian ranking of medical AI for doctors, with Ahpra, TGA and Privacy Act requirements in depth, including APP 8 and the 10 December 2026 automated-decision rules.
  29. Source 29. Best AI for GPs in Australia (EvidenceMD)The practice guide for Australian GPs: consent, RACGP expectations, the TGA's clinical decision support exemption and choosing and governing AI tools.

About EvidenceMD

EvidenceMD is a clinical reasoning platform for health professionals and medical and clinical researchers. It answers clinical questions from 40 million+ peer-reviewed papers and clinical guidelines with a visible chain of reasoning and a citation for every claim, in 30 languages, and needs no NPI or licence check; it is free to start. Application data is hosted in the United States, and it is not included in the ARTG. Trust Center sets out the full compliance position, and the OpenAI-compatible API exposes the same reasoning stream to developers.

Related reading

Best UpToDate alternative in Australia (2026)Best medical AI for doctors in Australia (2026)Best AI for GPs in AustraliaBest OpenEvidence alternative (2026)Best AI medical scribes in Australia (2026)

Cited clinical answers for Australian clinicians

Ask EvidenceMD a de-identified clinical question and read the reasoning and the sources behind the answer. No NPI needed, free to start.

Try EvidenceMD See the benchmark results